Chengdu Sino Biopharmaceutical Co., Ltd. (hereinafter referred to as Sino Biopharma) is a wholly-owned subsidiary of Chengdu Sino Biotech Co., Ltd., established in October 2004. It is recognized as a "Sichuan Province High-Tech Certified Enterprise" and "Sichuan Province Enterprise Technology Center," with a registered capital of 50 million RMB. The company possesses more than 50 key domestic and international peptide production technologies, making it a mature, specialized enterprise in domestic large-scale production of peptides and amino acid drugs, with single-batch production capacity reaching the kilogram level, and it is FDA-certified in the United States. Sino Biopharma focuses on peptides, classified as a "specialized, refined, distinctive, and innovative" enterprise and a national high-tech enterprise, and it went public in 2021. Sino Biopharma integrates research and development, production, and sales, with business covering peptide active pharmaceutical ingredients, cosme